June #36 : New Drug watch - by Staff

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Some Like It Hot

Body Snatchers

Sleeping With the Enemy

Out on a Lymphoma

ADAP or Perish

When Chemo Calls

Cliff Hanger

No Ordinary Patsy

Over Bite

Outlandish Behavior

Film Freak

Where to Find It

Milking It

Out of Africa

Nuke Wars

Cheap Sex

What a Croc

A Sari State

Karate Kid

Play Safe

Shot in the Arm

The Page Is the Rage

S.O.S

To the Editor

Touching Tale

Say What

Cosmo Confessions

Full of Spunk

POZ Picks

The Art of War

Obits

Bull Market

Final Analysis

The Secret Origin of Positoid

Wheels of Love

Party Favors

Cervix Service

Don’t Be So Sensitive

Hair Goes!

Hear Her Roar

Smear Campaign

If You Buy One Book...

Camp Heartland

Ladies First

New Drug watch



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 1998

New Drug watch

by Staff

1. Drug/ Company
2. For
3. Status
4. Standard Treatment
5. Notes
6. From the gut of PWA Stephen Gendin

1. Nitazoxanide/Unimed
2. Cryptosporidiosis
3. New Drug Application filed last December; FDA approval possible this summer
4. None approved; humatin often used
5. Trials found about 40 percent of PWAs had half the stool frequency; community reports of benefit from combo treatment.
6. “While far from a cure, everyone with crypto should try it, perhaps with other experimental treatments. With little on the horizon, this is the best we’ve got.”

1. Rituximab (Rituxan)/Genentech
2. Non-Hodgkin’s Lymphoma (NHL)
3. Approved for low-grade, CD20+-type lymphoma; Phase II underway for intermediate- and high-grade lymphoma
4. mBACoD, CHoP, other chemo
5. Monoclonal antibody. For all grades of lymphoma, 30 to 40 percent of (HIV-negative) people had some response. Low-graders had extremely good results when combining with CHoP.
6. “Trials are planned for people with HIV. Meantime, for the adventurous—or the desperate—this drug is definitely worth checking out, even without HIV-specific data.”

1. T-20 (Pentafuside)/Trimeris
2. HIV
3. Phase II underway
4. Highly active antiretroviral therapy (HAART)
5. Fusion inhibitor, aimed at preventing HIV’s fusion with T cells. Taken IV. In short dose-ranging study, all four PWAs on highest dose had viral loads drop to undetectable.
6. “The good news is, this is a new class of drugs. The bad news? The first drugs in a new class usually turn out to be a bust. Still, it’s encouraging that researchers are investigating meds other than protease inhibitors or nucleoside analogues.”

1. XQ-9302/Shanghai Xiong Qi Biological Products Co.
2. HIV
3. Phase I/II underway at AIDS Research Alliance (Los Angeles)
4. HAART
5. Powdered mix of 20 Chinese herbs—some disclosed, some not, due to a pending patent. Formula shown to have test-tube anti-HIV activity. A Shanghai study of five people found greater than one-log viral-load reduction sustained over nine months.
6. “It’s great that a highly respected community-based research group like AIDS Research Alliance is investigating alternative medicine—in a double-blind, placebo-controlled study, no less. But if this research is to be taken seriously, the complete recipe must be revealed.”



[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    Sloan1
    Dallas
    Texas


    Deelight4u
    BROOKLYN
    New York


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.